🏛️ Verified NIH Record • Updated 2026-02-05
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry (NCT05745389)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: CorEvitas
🩺 Plain-English Summary (8th-Grade Level)
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper limit for either target.
Who can join: Review the eligibility criteria below.
Location: CorEvitas, LLC — Waltham, Massachusetts
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- CorEvitas, LLC — Waltham, Massachusetts
📞 Contact the Study Coordinator
Phone: (508) 408-5435
Email: corevitasregistrytrials@corevitas.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alopecia Areata
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Birmingham, Alabama
- A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo — Northridge, California
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) — Northridge, California
- Alopecia Areata Registry — San Francisco, California
- Intralesional Cyclosporine for Alopecia Areata — Sacramento, California
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Scottsdale, Arizona
Explore by condition: All Alopecia Areata clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.